Ventfort
Aliases: Vascular peptide bioregulator
Last verified: 2026-09-23
The short version
An oral vascular peptide complex — endothelial and microcirculatory support. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian series in the elderly. Status: research chemical. Supplement status.
Identity & type
- Molecular type
- bioregulator
- Origin
- An oral vascular peptide complex — endothelial and microcirculatory support.
Mechanism of action
Vascular peptides; gene-regulatory endothelial modulation.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Ventfort. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–2 capsules/day, courses. A vascular peptide complex: circulatory support reported in the elderly; mild effects.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A vascular peptide complex: circulatory support reported in the elderly; mild effects.
Protocol — official vs community
Official / label
No approved protocol exists. Ventfort is an oral vascular peptide complex (cytomedin class) sold as a supplement; no registered drug product in any major market.
Duration: —
Supplement status only; Russian series in the elderly support the endothelial positioning without large randomized trials.
Community (anecdotal)
1–2 capsules daily for 10–30 days; oral peptide uptake is unproven.
- Cycle:
- 1–2 courses per year.
- Break:
- Months between courses.
The capsule regimen mirrors the shared bioregulator course structure; only the vascular/endothelial targeting claim distinguishes it from the other oral cytomedins.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian series in the elderly.
Preclinical evidence
Russian series in the elderly.
Known risks
- None reported.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.